There are still many challenges in gene therapy analytics and manufacturing according to gene therapy developers. Our Global Technical Director, Alfred Luitjens was interviewed on this topic by Genetic Engineering & Biotechnology News. The interview was in response to his presentation on the manufacturing of a lentiviral vector for a gene therapy against RAG1-SCID at the PepTalk conference 2020.
Link to full article.
Why is scale-up of viral vaccines and viral vector products for clinical phase testing so challenging? Here are 5 of the biggest pitfalls.
Adenovirus vectors are vital to gene therapy, vaccine development, and cancer virotherapies. Learn more about these important delivery tools.
The road from R&D to final production of an adenoviral vector product is well trodden. Here is information to help you on your journey.
Related
Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.
